Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration
TOKYO, May 8, 2023 – (JCN Newswire) – Eisai Co., Ltd. announced today that it has entered into a joint development agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd., for BB-1701, an antibody-drug conjugate (ADC) with option rights for a strategic collaboration. BB-1701 is an ADC that is composed of Eisai’s in-house developed anticancer agent eribulin…
Read More
0
